Recce Pharmaceuticals Ltd. (AU:RCE)
ASX:RCE
Top Page
Recce Pharmaceuticals Ltd.
(Sydney:RCE)
Select Model
Select Model
Rating:41Neutral
Price Target:
AU$0.51
▲(24.63% Upside)
Action:ReiteratedDate:03/04/26
The score is pressured primarily by poor financial performance (declining revenue, severe losses, and negative equity). Technical indicators also point to strong bearish momentum, while valuation offers limited support due to negative earnings and no dividend yield provided.
Positive Factors
Innovative anti-infective platform
Recce’s synthetic polymer antibiotic platform targets drug-resistant infections, providing a differentiated technological moat and multiple program pathways. A platform model supports sustained value creation through staged clinical validation, regulatory milestones and licensing opportunities rather than one-off product bets.
Negative Factors
Material revenue decline
A 21.73% revenue decline signals weakening commercial or partner-derived income. For a clinical-stage biotech that relies on limited cash reserves and external funding, falling revenue compresses runway, increases financing needs and raises the risk of program delays or unfavorable capital raises that impair long-term progress.
Read all positive and negative factors
Positive Factors
Negative Factors
Innovative anti-infective platform
Recce’s synthetic polymer antibiotic platform targets drug-resistant infections, providing a differentiated technological moat and multiple program pathways. A platform model supports sustained value creation through staged clinical validation, regulatory milestones and licensing opportunities rather than one-off product bets.
Read all positive factors
Recce Pharmaceuticals Ltd. (RCE) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$138.81M
Dividend YieldN/A
Average Volume (3M)154.69K
Price to Earnings (P/E)―
Beta (1Y)0.71
Revenue GrowthN/A
EPS Growth0.66%
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.06
Shares Outstanding289,183,400
10 Day Avg. Volume112,630
30 Day Avg. Volume154,688
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)-22.52
Price to Sales (P/S)9.15
P/FCF Ratio-3.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.13
Revenue Forecast (FY)N/A
Recce Pharmaceuticals Ltd. Business Overview & Revenue Model
Company Description
Recce Pharmaceuticals Ltd. (RCE) is a biotechnology company focused on the development and commercialization of innovative anti-infective therapies. The company specializes in creating synthetic polymers to combat serious infections, particularly ...
How the Company Makes Money
null...
Recce Pharmaceuticals Ltd. Financial Statement Overview
Summary
Income Statement
25
Negative
Balance Sheet
30
Negative
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 562.52K | 7.51M | 5.03M | 4.37M | 3.08M | 1.64M |
| Gross Profit | -1.56M | -2.94M | -2.19M | 4.15M | 2.90M | 1.34M |
| EBITDA | -26.98M | -20.33M | -21.35M | -16.99M | -13.87M | -14.77M |
| Net Income | -30.25M | -21.43M | -17.66M | -13.08M | -10.99M | -13.51M |
Balance Sheet | ||||||
| Total Assets | 2.04M | 12.41M | 6.37M | 2.56M | 12.62M | 21.68M |
| Cash, Cash Equivalents and Short-Term Investments | 602.99K | 10.45M | 4.42M | 1.56M | 11.58M | 20.87M |
| Total Debt | 11.26M | 10.77M | 811.19K | 250.57K | 74.76K | 126.95K |
| Total Liabilities | 20.66M | 15.47M | 15.89M | 5.14M | 2.56M | 1.18M |
| Stockholders Equity | -18.62M | -3.05M | -9.52M | -2.59M | 10.06M | 20.50M |
Cash Flow | ||||||
| Free Cash Flow | -23.79M | -20.47M | -13.15M | -12.73M | -9.05M | -7.93M |
| Operating Cash Flow | -23.75M | -20.44M | -13.01M | -12.69M | -9.01M | -7.86M |
| Investing Cash Flow | 115.85K | -443.90K | -141.90K | -38.63K | -40.34K | -76.01K |
| Financing Cash Flow | 22.06M | 26.92M | 16.00M | 2.71M | -240.50K | 26.12M |
Recce Pharmaceuticals Ltd. Technical Analysis
Positive
0.41
Price Trends
0.52
Negative
0.55
Negative
0.47
Positive
Market Momentum
-0.01
Negative
49.29
Neutral
48.15
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:RCE, the sentiment is Positive. The current price of 0.41 is below the 20-day moving average (MA) of 0.47, below the 50-day MA of 0.52, and below the 200-day MA of 0.47, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 49.29 is Neutral, neither overbought nor oversold. The STOCH value of 48.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:RCE.
Recce Pharmaceuticals Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$112.42M | -14.80 | -40.65% | ― | 700.00% | 26.88% | |
47 Neutral | AU$79.53M | -3.83 | -24.81% | ― | ― | 26.64% | |
42 Neutral | AU$58.88M | -5.28 | -62.49% | ― | ― | 10.78% | |
41 Neutral | AU$138.81M | -2.84 | 279.21% | ― | ― | 0.66% | |
41 Neutral | AU$49.98M | -0.70 | -134.65% | ― | ― | 55.94% | |
41 Neutral | AU$97.88M | -2.12 | -30.19% | ― | ― | 63.46% |
* Healthcare Sector Average
AU:RCE
Recce Pharmaceuticals Ltd.
0.48
0.18
61.62%
AU:ATX
Amplia Therapeutics
0.16
0.10
192.45%
AU:IMU
Imugene
0.14
-0.74
-84.16%
AU:ATH
Alterity Therapeutics
0.01
0.00
0.00%
AU:PTX
Prescient Therapeutics Limited
0.06
0.01
33.33%
AU:ALA
Arovella Therapeutics Limited
0.09
0.01
16.25%
Recce Pharmaceuticals Ltd. Corporate Events
Recce Wins Brazilian Patent for Broad-Spectrum Anti-Infective Portfolio
Mar 24, 2026
Recce Pharmaceuticals has secured a key Brazilian patent for its RECCE 327 and RECCE 529 anti-infective compounds, extending protection to 2041 and covering their preparation, broad therapeutic use against multiple infections, and diverse delivery...
Recce Pharmaceuticals Issues Webinar Disclaimer on Investor Information and U.S. Offer Restrictions
Mar 18, 2026
Recce Pharmaceuticals has released a webinar presentation primarily comprising standard disclaimers on the nature of its materials and legal limitations on reliance by prospective investors. The document emphasizes that the presentation is not fin...
Recce Pharmaceuticals Schedules Investor Webinar to Highlight Key Anti-Infective Programs
Mar 17, 2026
Recce Pharmaceuticals will host a live online investor webinar on 19 March 2026 to update stakeholders on its advancing anti-infective programs. The session, held via Zoom and later available as a recording, aims to broaden investor understanding ...
Recce Pharmaceuticals Deepens R&D-Driven Loss as Anti-Infective Programs Advance
Feb 27, 2026
Recce Pharmaceuticals reported a widened half-year loss of $16.6 million to 31 December 2025, more than doubling the prior period as it increased research and development spending, with net tangible assets per share falling further into negative t...
Recce Pharmaceuticals Director Options Lapse Following Scheduled Expiry
Feb 24, 2026
Recce Pharmaceuticals reported a change in the securities held by director James Graham, following the expiry and lapse of 2,250,000 unlisted options exercisable at $1.56 on 22 February 2026. After the change, Graham retains 3,000,000 unlisted opt...
Recce Pharmaceuticals Options Lapse, Simplifying Capital Structure
Feb 24, 2026
Recce Pharmaceuticals has announced the cessation of 8,415,000 listed options (RCEAN) that expired unexercised on 22 February 2026, each carrying an exercise price of A$1.56. The expiration of these options slightly simplifies the company’s ...
Recce Pharmaceuticals Deepens U.S. Army Ties With New Burn Wound Gel Study
Feb 1, 2026
Recce Pharmaceuticals has signed a new Cooperative Research and Development Agreement with the U.S. Army Institute of Surgical Research to evaluate its RECCE 327 Gel in a validated burn wound infection model that mimics battlefield injuries. The s...
Recce Advances Phase 3 Diabetic Foot Trial and Strengthens Anti-Infective Pipeline
Jan 30, 2026
Recce Pharmaceuticals reported significant operational progress in its second quarter of FY2026, advancing its registrational Phase 3 clinical trial of RECCE 327 topical gel for diabetic foot infections in Indonesia, one of the world’s large...
Recce Pharmaceuticals Secures $5.3m R&D Rebate to Bolster Anti-Infective Pipeline
Jan 14, 2026
Recce Pharmaceuticals has received an AUD $5.34 million cash refund under Australia’s 43.5% Research Development Tax Incentive for eligible RD activities undertaken in the 2025 financial year, providing non-dilutive funding to support its c...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.